Resistance at Virological Failure Using Boosted Protease Inhibitors Versus Nonnucleoside Reverse Transcriptase Inhibitors As First-Line Antiretroviral Therapy—Implications for Sustained Efficacy of ART in Resource-Limited Settings

First Line ◽

Sustained Efficacy ◽

Superiority of Protease Inhibitors over Nonnucleoside Reverse-Transcriptase Inhibitors when Highly Active Antiretroviral Therapy Is Resumed after Treatment Interruption

Clinical Infectious Diseases ◽

10.1086/432887 ◽

2005 ◽

Vol 41 (6) ◽

pp. 897-900 ◽

Cited By ~ 8

Author(s):

P. Barreiro ◽

C. de Mendoza ◽

J. Gonzalez-Lahoz ◽

V. Soriano

Keyword(s):

Antiretroviral Therapy ◽

Reverse Transcriptase ◽

Protease Inhibitors ◽

Highly Active Antiretroviral Therapy ◽

Treatment Interruption ◽

Highly Active

Pharmacogenetics of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in resource-limited settings: Influence on antiretroviral therapy response and concomitant anti-tubercular, antimalarial and contraceptive treatments

Infection Genetics and Evolution ◽

10.1016/j.meegid.2015.11.014 ◽

2016 ◽

Vol 37 ◽

pp. 192-207 ◽

Cited By ~ 13

Author(s):

Gianluca Russo ◽

Giacomo Maria Paganotti ◽

Sandra Soeria-Atmadja ◽

Miriam Haverkamp ◽

Doreen Ramogola-Masire ◽

...

Keyword(s):

Antiretroviral Therapy ◽

Reverse Transcriptase ◽

Therapy Response ◽

Nucleoside Reverse Transcriptase Inhibitors ◽

Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues

HIV Medicine ◽

10.1111/hiv.12044 ◽

2013 ◽

Vol 14 (9) ◽

pp. 571-577 ◽

Cited By ~ 7

Author(s):

MM Santoro ◽

C Sabin ◽

F Forbici ◽

L Bansi ◽

D Dunn ◽

...

Keyword(s):

Drug Resistance ◽

Antiretroviral Therapy ◽

Reverse Transcriptase ◽

First Line ◽

Resistance Development ◽

Hiv 1

Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study

The Lancet HIV ◽

10.1016/s2352-3018(16)30189-8 ◽

2017 ◽

Vol 4 (1) ◽

pp. e13-e20 ◽

Cited By ~ 4

Author(s):

Mark A Boyd ◽

Janaki Amin ◽

Patrick W G Mallon ◽

Nagalingeswaran Kumarasamy ◽

Johan Lombaard ◽

...

Keyword(s):

Body Composition ◽

Antiretroviral Therapy ◽

Reverse Transcriptase ◽

Virological Failure ◽

Second Line ◽

First Line ◽

Open Label ◽

Therapy Regimen ◽

Metabolic Outcomes

PIN20 THE COST-EFFECTIVENESS OF ANTIRETROVIRAL REGIMENS CONTAINING PROTEASE INHIBITORS (PIS) OR NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTI) IN THE TREATMENT OF HIV-INFACTED INDIVIDUALS IN POLAND

Value in Health ◽

10.1016/s1098-3015(10)61498-2 ◽

2002 ◽

Vol 5 (6) ◽

pp. 569

Author(s):

E Kowalik ◽

MK Jakubczyk ◽

MP Niewada ◽

B Kamiñski

Keyword(s):

Cost Effectiveness ◽

Reverse Transcriptase ◽

Protease Inhibitors ◽

The Cost

Reconsidering First‐Line Antiretroviral Therapy in Resource‐Limited Settings: The Need for Operational Research

The Journal of Infectious Diseases ◽

10.1086/597810 ◽

2009 ◽

Vol 199 (9) ◽

pp. 1407-1408 ◽

Cited By ~ 1

Author(s):

P. Richard Harrigan ◽

Viviane Dias Lima ◽

Julio S. Montaner

Keyword(s):

Antiretroviral Therapy ◽

Operational Research ◽

First Line ◽

Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor

Journal of Antimicrobial Chemotherapy ◽

10.1093/jac/dky211 ◽

2018 ◽

Vol 73 (9) ◽

pp. 2480-2484 ◽

Cited By ~ 9

Author(s):

C Spertilli Raffaelli ◽

B Rossetti ◽

L Paglicci ◽

M Colafigli ◽

G Punzi ◽

...

Keyword(s):

Drug Resistance ◽

Antiretroviral Therapy ◽

Protease Inhibitor ◽

Reverse Transcriptase ◽

Integrase Inhibitor ◽

First Line ◽

Hiv 1

What Is the Optimal First Line Antiretroviral Therapy in Resource-Limited Settings?

PLoS Medicine ◽

10.1371/journal.pmed.1001291 ◽

2012 ◽

Vol 9 (8) ◽

pp. e1001291 ◽

Cited By ~ 2

Author(s):

Chris Kenyon ◽

Robert Colebunders

Keyword(s):

Antiretroviral Therapy ◽

First Line ◽

Induction with Lopinavir-Based Treatment Followed by Switch to Nevirapine-Based Regimen versus Non-Nucleoside Reverse Transcriptase Inhibitors-Based Treatment for First Line Antiretroviral Therapy in HIV Infected Children Three Years and Older

PLoS ONE ◽

10.1371/journal.pone.0108063 ◽

2014 ◽

Vol 9 (9) ◽

pp. e108063 ◽

Cited By ~ 1

Author(s):

Gerardo Alvarez-Uria ◽

Raghavakalyan Pakam ◽

Praveen Kumar Naik ◽

Manoranjan Midde

Keyword(s):

Antiretroviral Therapy ◽

Reverse Transcriptase ◽

Nucleoside Reverse Transcriptase Inhibitors

First Line ◽

Differential Impact of Resistance-Associated Mutations to Protease Inhibitors and Nonnucleoside Reverse Transcriptase Inhibitors on HIV-1 Replication Capacity

AIDS Research and Human Retroviruses ◽

10.1089/aid.2013.0038 ◽

2013 ◽

Vol 29 (8) ◽

pp. 1117-1122 ◽

Cited By ~ 2

Author(s):

Szu-Min Hsieh ◽

Sung-Ching Pan ◽

Sui-Yuan Chang ◽

Chien-Ching Hung ◽

Wang-Huei Sheng ◽

...

Keyword(s):

Reverse Transcriptase ◽

Protease Inhibitors ◽

Replication Capacity ◽

Differential Impact ◽

Hiv 1